COMPANY

Lexeo Therapeutics

HQ: New York, NY source · lexeotx.com ↗ · Mid-Atlantic

4 open jobs · last seen Oct 23, 2026 · 19 sources

Keywords: cardiovascular cardiomyopathy dilated cardiomyopathy gene therapy AAV Friedreich Ataxia Arrhythmogenic Cardiomyopathy PKP2-ACM PKP2-ARVC Secondary Cardiomyopathy Alzheimer Disease Early Onset Alzheimer Disease osteoporosis esophageal cancer LX1001 LX2006 LX2020

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Since the raise (Oct 20, 2025): 4 of 4 open jobs were first seen after it.

4Open jobs $233.8MRaised (2 yrs)8Trials (company is sponsor)7NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Research Associate I/II, Preclinical Research (Contract)	New York	Oct 15, 2026	Oct 17, 2026
Manager/Senior Manager, CMC Quality Control	New York	Sep 15, 2026	Oct 5, 2026
Director/Senior Director, Clinical Development	New York	May 14, 2026	Oct 5, 2026
Lab Operations Associate Scientist/Scientist I (Contract)	New York	May 7, 2026	Oct 20, 2026

See all 4 jobs

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (4 open jobs at last check). source ↗
Sep 22, 2026 Partnership Partnership / licensing announced Sep 22, 2026. Source: SEC filing. source ↗
Jun 25, 2026 Trial start Phase 2: Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy source ↗
Oct 20, 2025 Raise Follow-on offering: $153.8M (total, as published), announced Oct 20, 2025. Source: company release on GlobeNewswire. source ↗
Sep 30, 2025 Trial start —: Clinical Course Of Disease In Participants With FA-CM source ↗
Aug 29, 2025 Trial start —: Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant source ↗
May 27, 2025 Raise Private placement: $80M (total, as published), announced May 27, 2025. Source: SEC filing. source ↗
Feb 29, 2024 Trial start Phase 1/Phase 2: Gene Therapy for ACM Due to a PKP2 Pathogenic Variant source ↗
Jan 23, 2024 Trial start —: A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM source ↗
May 8, 2023 Trial start Phase 1: Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease source ↗
Aug 24, 2022 Trial start Phase 1/Phase 2: Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia source ↗
Nov 6, 2019 Trial start Phase 1/Phase 2: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1/Phase 2 · Gene Therapy for ACM Due to a PKP2 Pathogenic Variant · NCT06109181
2027-07 (ESTIMATED) · · A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM · NCT06976606
2027-09 (ESTIMATED) · · Clinical Course Of Disease In Participants With FA-CM · NCT06865482
2028-11 (ESTIMATED) · Phase 1 · Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease · NCT05400330
2029-09 (ESTIMATED) · Phase 1/Phase 2 · Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia · NCT05445323
2030-08 (ESTIMATED) · · Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant · NCT07050160
2032-06 (ESTIMATED) · Phase 2 · Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy · NCT07721025

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 4

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Research Associate I/II, Preclinical Research (Contract)	New York	Oct 15, 2026	Oct 17, 2026	Not stated
Manager/Senior Manager, CMC Quality Control	New York	Sep 15, 2026	Oct 5, 2026	Senior
Director/Senior Director, Clinical Development	New York	May 14, 2026	Oct 5, 2026	Senior
Lab Operations Associate Scientist/Scientist I (Contract)	New York	May 7, 2026	Oct 20, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $233.8M. Last 2 years.

Oct 20, 2025 Follow-on offering: $153.8M (total, as published), announced Oct 20, 2025. Source: company release on GlobeNewswire. source ↗
May 27, 2025 Private placement: $80M (total, as published), announced May 27, 2025. Source: SEC filing. source ↗
Sep 22, 2026 Partnership / licensing announced Sep 22, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT07721025	Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy	Phase 2	Recruiting	Jun 25, 2026	2032-06 (estimated)
NCT06865482	Clinical Course Of Disease In Participants With FA-CM	Not listed	Recruiting	Sep 30, 2025	2027-09 (estimated)
NCT05445323	Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia	Phase 1/Phase 2	Active, not recruiting	Aug 24, 2022	2029-09 (estimated)
NCT07050160	Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant	Not listed	Enrolling by invitation	Aug 29, 2025	2030-08 (estimated)
NCT06109181	Gene Therapy for ACM Due to a PKP2 Pathogenic Variant	Phase 1/Phase 2	Active, not recruiting	Feb 29, 2024	2026-12 (estimated)
NCT03634007	Gene Therapy for APOE4 Homozygote of Alzheimer's Disease	Phase 1/Phase 2	Completed	Nov 6, 2019	Nov 7, 2024 (actual)
NCT05400330	Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease	Phase 1	Active, not recruiting	May 8, 2023	2028-11 (estimated)
NCT06976606	A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM	Not listed	Recruiting	Jan 23, 2024	2027-07 (estimated)

NIH awards 7

Annual award amounts. Total $2.9M.

Jul 27, 2020 NIH award 1R41NS117265-01 FY2020: $499,916 awarded for that fiscal year; activity R41 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. CNS Gene Therapy for CLN2 Disease Using source ↗
Jul 19, 2020 NIH award 5R42HL140670-03 FY2020: $341,571 awarded for that fiscal year; activity R42 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Oxidation-resistant Anti-protease Thera source ↗
Jun 16, 2020 NIH award 1R41AA028465-01 FY2020: $252,042 awarded for that fiscal year; activity R41 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Gene Therapy to Treat Ethanol-induced O source ↗
Sep 23, 2019 NIH award 1R41HL145871-01A1 FY2019: $224,593 awarded for that fiscal year; activity R41 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Gene Therapy to Protect the Lung from source ↗
May 23, 2019 NIH award 1R41AA027739-01 FY2019: $224,970 awarded for that fiscal year; activity R41 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Gene Therapy to Prevent Esophageal Canc source ↗
May 20, 2019 NIH award 4R42HL140670-02 FY2019: $1,157,532 awarded for that fiscal year; activity R42 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Oxidation-resistant Anti-protease The source ↗
Feb 2, 2018 NIH award 1R42HL140670-01 FY2018: $224,967 awarded for that fiscal year; activity R42 (STTR); PI CRYSTAL, RONALD G; recipient as written: LEXEO THERAPEUTICS, LLC, NEW YORK, NY. Oxidation-resistant Anti-protease Thera source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

Connect

See your connections at Lexeo Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18